Reprint from Patient Care

Director of the Brigham and Women’s Diabetes Program Marie McDonnell, MD, talked with our editor about 2020 studies on SGLT-2 inhibitors, insulin icodec, and more.
January 29, 2021

Director of the Brigham and Women’s Diabetes Program Dr Marie McDonnell talked with Patient Care Online in late December about 2020’s landmark SGLT2 inhibitor studies and recommended what areas of research show greatest promise for 2021 and beyond.

For example, look for phase 3 data this year from the studies on once-weekly insulin icodec–an approach to treatment that could be life-altering for millions who rely on daily insulin shots. Then, follow the ongoing work to develop “safe depot” drug administration across therapeutic areas, advises McDonnell.

McDonnell also believes that cell-based therapy, ie, beta-cell replacement, and gene editing procedures such as CRISPR will be increasingly applied to and successful in the treatment of both type 1 and advanced type 2 diabetes.




I have functioned as a Business and Media Consultant over the past sixteen years and spent many years developing my capacity to function in our ever evolving use of technology, communication, education and training.